Valproate Versus Propranolol in Migraine

PHASE4RecruitingINTERVENTIONAL
Enrollment

600

Participants

Timeline

Start Date

January 23, 2023

Primary Completion Date

July 1, 2024

Study Completion Date

July 5, 2024

Conditions
Migraine Disorders
Interventions
DRUG

Valproic Acid 500 MG

The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The treatment safety was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.

DRUG

Propranolol

The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The treatment safety was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.

Trial Locations (1)

33511

RECRUITING

Kafr Elsheikh University Hospital, Kafr ash Shaykh

All Listed Sponsors
lead

Kafrelsheikh University

OTHER